These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11808755)

  • 1. Impact of mutations conferring reduced susceptibility to lamivudine on the response to antiretroviral therapy.
    Perno CF; Cozzi-Lepri A; Balotta C; Forbici F; Violin M; Bertoli A; Facchi G; Pezzotti P; Angarano G; Arici C; Narciso P; Orani A; Raise E; Scalzini A; Poggio A; Ippolito G; Moroni M; Monforte AD;
    Antivir Ther; 2001 Sep; 6(3):195-8. PubMed ID: 11808755
    [No Abstract]   [Full Text] [Related]  

  • 2. A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.
    Ross LL; Dretler R; Gerondelis P; Rouse EG; Lim ML; Lanier ER
    AIDS; 2006 Mar; 20(5):787-9. PubMed ID: 16514317
    [No Abstract]   [Full Text] [Related]  

  • 3. Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
    Tamalet C; Tomei C; Henry M; Solas C; Villacian J; Colson P
    AIDS; 2007 Nov; 21(18):2551-2. PubMed ID: 18025898
    [No Abstract]   [Full Text] [Related]  

  • 4. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
    Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
    Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial).
    Antivir Ther; 2002 Mar; 7(1):11-20. PubMed ID: 12008783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1.
    Turner D; Brenner B; Wainberg MA
    J Antimicrob Chemother; 2004 Jan; 53(1):53-7. PubMed ID: 14645322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors.
    Fitzgibbon JE; DiCola B; Arnold E; Das K; Sha BE; Pottage JC; Nahass R; Gaur S; John JF
    Antivir Ther; 2001 Dec; 6(4):231-8. PubMed ID: 11878404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
    Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
    HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological recovery despite virological failure is independent of human immunodeficiency virus-type 1 resistant mutants in children receiving highly active antiretroviral therapy.
    Chiappini E; Galli L; Zazzi M; de Martino M
    J Med Virol; 2003 Aug; 70(4):506-12. PubMed ID: 12794711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
    Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
    Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
    Demeter LM; Ribaudo HJ; Erice A; Eshleman SH; Hammer SM; Hellmann NS; Fischl MA;
    Clin Infect Dis; 2004 Aug; 39(4):552-8. PubMed ID: 15356820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance mutations during structured treatment interruptions.
    Yerly S; Fagard C; Günthard HF; Hirschel B; Perrin L;
    Antivir Ther; 2003 Oct; 8(5):411-5. PubMed ID: 14640388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.
    Saracino A; Monno L; Scudeller L; Cibelli DC; Tartaglia A; Punzi G; Torti C; Lo Caputo S; Mazzotta F; Scotto G; Carosi G; Angarano G
    J Med Virol; 2006 Jan; 78(1):9-17. PubMed ID: 16299731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities.
    Weinstock HS; Zaidi I; Heneine W; Bennett D; Garcia-Lerma JG; Douglas JM; LaLota M; Dickinson G; Schwarcz S; Torian L; Wendell D; Paul S; Goza GA; Ruiz J; Boyett B; Kaplan JE
    J Infect Dis; 2004 Jun; 189(12):2174-80. PubMed ID: 15181563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of lamivudine resistance associated mutations in pol-gene of HIV-1 in patients from north India: a preliminary report.
    Sachdeva N; Sehgal S; Sud A; Datta U; Arora SK
    Indian J Pathol Microbiol; 2005 Jul; 48(3):337-40. PubMed ID: 16761745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Piyavong B; Chumpathat N; Chantratita W
    Clin Infect Dis; 2007 Feb; 44(3):447-52. PubMed ID: 17205457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.